Verinurad
As of the edition of 20 October 2026, Verinurad is a small molecule: in active development; acts on SLC22A12.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2014
- Kind
- Small molecule
- Registered trials
- 22, 0 stopped early
- Disease areas
- Nutrition and metabolism; Bones, joints and muscles; Inherited and neonatal; Pregnancy and women's health; Urinary and reproductive; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC22A12 | Solute carrier family 22 member 12 | Q96S37 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 13 | 13 | 0 | 0 |
| Phase 2 | 9 | 9 | 0 | 0 |
| All trials | 22 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Ardea Biosciences | Lead sponsor of trials | 2013 to now |
| AstraZeneca | Lead sponsor of trials | 2014 to now |